As compared with related HLA-identical sibling donors, bone marrow transplantation (BMT) with phenotypically HLA ABDR-compatible unrelated donors is associated with increased mortalii. This may be due to hidden HLA incompatibiliiies not detected by conventional typing. We have analyzed 44 unrelated patient-donor pairs who were matched for HLA-A, -B, and -DR by routine tissue typing. Our comprehensive HLA typing approach consisted of serology, cytotoxic T-cell precursor (CTLp) tests, T-cell cloning, oligotyping, and DNA sequencing. Using these techniques, we identified numerous HLA allele mismatches not detected by the previously applied routine typing. Twenty-four patientdonor pairs were highly matched and had a low CTLp frequency, whereas the remaining 20 pairs were allele-mis-
A an accepted treatment for numerous hematologic disorders.'" The success rate of BMT has steadily increased in recent years, but graft-versus-host disease (GVHD) and other immune dysfunctions are still major causes of posttransplant mortality?. ' The degree of HLA compatibility between patient and donor significantly influences the incidence and severity of such complications."" Only about 35% of patients have a genotypically HLAidentical sibling donor. For many of the remaining patients it is now possible to find an HLA ABDR-compatible unrelated donor among approximately 2.6 million volunteers so far registered. However, it is important to note that such donors will only be phenotypically (but not genotypically) HLA matched. Moreover, there is distinct evidence that fine HLA specificities frequently differ between conventionally typed HLA ABDR-compatible unrelated individuals,"-'6 a relevant finding for graft 0utc0me.l~ Because standard HLA typing techniques do not discriminate between many of the existing (and in part as yet not characterized) polymorphic HLA alleles, an unrelated donor might be phenotypically ABDRcompatible but nevertheless incompatible at the DNA sequence level for one or more HLA alleles.
Compared with HLA genotypically identical related BMT, unrelated grafting is associated with a higher mortality
We addressed the hypothesis that this may be due to HLA allele mismatches undetected by routine typing methods.
PATIENTS AND METHODS
All 34 consecutive transplants performed in the years 1990 through 1994 in patients from Switzerland were included in this study; no patients were excluded. In addition, all patients (5) from Helsinki and all patients (5) from Hamburg for whom sufficient blood cells had been cryopreserved to allow cytotoxic T-lymphocyte precursor (CTLp) and HLA subtype analysis were included.
Diagnoses, stage of disease at the time of transplantation, age of patients and donors, cytomegalovirus (CMV) serology, preconditioning, and GVHD prophylaxis are. shown in Table 1 . Forty percent of the donors were. female (55% in the matched and 22% in the mismatched group), 48% of the patients were female (48% and
Patient population.
matched for HLA-A,-B,-C,-DR,-DO antigens and/or had a positive result of the CTLp test. Patient and donor age, diagnosis, and treatment did not differ significantly between the matched and mismatched transplants. The probability for severe acute graft-versus-host disease grades Ill-IV was 21% in the matched and 47% in the mismatched patients ( P = .0464). Transplant-related mortality was 21% and 57% ( P = .0072) and actuarial patient survival rates at 3 years were 61% and 13% ( P = .0005). We conclude that both HLA class I and class II allele mismatches between unrelated phenotypically ABDR-compatible patient-donor pairs are frequent and associated with increased incidence of posttransplant complications.
0 1996 by The American Society of Hematology. 47%), and 45% of the transplants were sex-mismatched (61% and 32%). There was no statistically significant difference between matched and mismatched grafts with respect to diagnosis, age, sex matching, CMV serology, preconditioning, and GVHD prophylaxis.
According to our selection policy, no unrelated donors other than those who were HLA ABDR compatible defined by HLA-A and -B serology (including splits) and generic oligotyping for HLA DR1-14 were accepted for BM donation. Blood samples of the 44 patients and 167 unrelated donors recruited through the unrelated BM donor registries were. analyzed. Each patient received a transplant from the donor who had the highest achievable HLA-compatibility. HLA-A and -B was typed by serology. The subtypes of HLA-A2, -A3, -B7, -B35, and -B44 were determined as described.I6.ls HLA-C sequence-specific oligonucleotide (SS0)-oligotyping was performed using an HLA-C specific polymerase chain reaction (PCR) with primers 5CInl-61 and 3BCIn3-12,I9 followed by hybridization with 26 SSO probes including 19 probes from Kennedy et alZo implemented with 7 probes testing codons 435, A73, R91, H129, E155, K173, and S178. Hybridization pattems obtained with these 26 probes allowed the discrimination of 23 HLA-C alleles. HLA-DRB DNA typing was performed by the DR microtiter plate oligotyping assay:' and additional Abbreviation: n, number of patients. Relapse refers to patients with acute leukemia in relapse; accelerated phase and blast crisis refer to patients with advanced chronic myeloid leukemia. The mean 2 SD time from diagnosis to transplantation was 603 2 267 and 680 i-494 days for the matched and mismatched groups, respectively. DRB 1 subtypes, DQB 1, and DPB 1 alleles were determined by hybridization with SSO probes after PCR amplifi~ation.'~.~~ The CTLp test was conducted in GVH direction as described by Kaminski et al." The test result was considered positive when the precursor frequency was 3 or more per million peripheral blood mononuclear cells (PBMCs). Subsequently, we generated CTL clones from the positive wells of the CTLp test, which confirmed its positive result and allowed the characterization of the mismatched HLA antigens using panel cells expressing various HLA phenotypes. Finally, the HLA alleles encoding the incompatible antigens recognized by the CTL clones were analyzed by DNA sequencingz4 andor oligotyping as described above. No HLA-A or -B allele differences could be detected in 24 of 25 unrelated control pairs with a negative result of a CTLp test. Therefore, a negative CTLp test result was predictive for HLA-A and -B compatibility at the allele (sequence) making it nonessential to molecularly type all HLA-A and -B alleles of the CTLp-negative patient-donor pairs. In parallel to the CTLp test performed in GVH direction, all incompatibilities in GVH direction (donor homozygous/patient heterozygous) but not in rejection direction (patient homozygous/donor heterozygous) were considered as mismatches.
Patients received transplants in the five different centers (University Hospitals of Basel, Geneva, Hamburg, Helsinki, and Zurich). Preconditioning was as indicated in Table l . Preconditioning of the 6 nonleukemic patients was fractionated total body irradiation (3/6), total lymphoid irradiation (1/6), cyclophosphamid (4/6), busulphan (2/6), and VP16 (3/6). GVHD prophylaxis ( Table 1) was comparable in the matched and mismatched groups. In vivo T-cell depletion, cyclosporin A (CsA), and methotrexate (MTX) were applied in 28% of the patients (29% in the matched
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and 26% in the mismatched group); in vivo T-cell depletion and CsA in 7% (4% and 11%); CsA and MTX in 61% (63% and S8%), and CsA alone in 4% (4% and 5%). In vivo T-cell depletion used the monoclonal antibody Campath-1G (day -4 to + S ; 10 mg/d intravenously). GVHD was classified according to the criteria described by Glucksberg et aLZ6
All patients were observed throughout the entire study period (January 1990 through May 1995) and for at least 6 months after BMT or until death. The mean 5 SD follow-up of surviving patients was 866 2 529 and 926 ? 526 days for the matched and mismatched groups, respectively. The Kaplan-Meier method and the logrank-test were used to calculate and compare the probabilities of GVHD, transplant-related mortality (TRM), and survival. 27 The remaining parameters were assessed using the x2 test. Not significant (NS) is indicated where P > .OS.
Statistics.

RESULTS
HLA incompatibilities not identified by routine HLA typing were detected using high-resolution HLA-matching techniques. Whereas 24 (55%) of the patient-donor pairs were HLA matched for A, B, C, DRB1, B3, B5, DQBl alleles (Table 2a) , mismatches were found in 20 (45%) pairs (Table  2b ; HLA mismatches in bold characters). In 9 patient-donor pairs there were mismatches for DRB 1/B3/B5 and/or DQB I alleles. Three of them were mismatched for two alleles, either DRBIDQBl, DRBl/BS, or DQBl/C (UPN 376, 420, and 326). The remaining 11 patient-donor pairs were matched for class I1 antigens but mismatched for HLA-A, -B, -C andor had positive CTLp test results (Table 2b ). The subsequent cellular and molecular analysis confirmed that the CTL activity was in most cases directed against mismatched HLA class I antigens. The CTLp test result was positive in all cases of HLA-4, -B, or -C mismatches, with the exception of 2 patient-donor pairs with HLA-C incompatibilities (UPN 298 and 145). Furthermore, there were 3 CTLp-positive patient-donor pairs (UPN 285, 390, and 440) without detectable HLA mismatches but with CTL clones specific to particular HLA class I antigens. We could not identify structural differences of these antigens indicating that the CTLs reacted against mismatched minor transplantation antigens. In summary, we identified 20 patient-donor pairs with HLA mismatches and/or a positive CTLp test. Full compatibility for HLA-A, -B, -C, -DRB, -DQB and a negative CTLp test was found in 24 patient-donor pairs. In the following, we will refer to the former 20 as the mismatched transplants and the latter 24 as the matched transplants.
HLA-DPB1 oligotyping revealed that only 8 (18%) patient-donor pairs were DPBl matched (23% in the matched and 13% in the mismatched group). Because of this high mismatch frequency, DPBl compatibility was not taken into account for allocation to the matched and mismatched groups.
High degree acute GVHD grade 111-IV was observed in 21% of the matched and 47% of the mismatched transplants ( P = .0464, Table 3 ). In contrast, there was no difference in moderate to severe acute GVHD grade 11-IV. The mean grade of skin GVHD was also similar in the two groups, but the mean grade of liver and gut GVHD was significantly higher in patients receiving mismatched grafts. The inciFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From Table 2a and b shows HLA typing, CTLp test results, acute GVHD, and survival of the matched and the mismatched patients, respectively. The precise HLA matching was determined as described in Patients and Methods. Patient-donor pairs matched for all the HLA-A, -6, -C, -DRBl/ B3/65, and -DQB1 alleles, and with a negative CTLp test result, were assigned to the matched group (Table 2a) . In contrast, the mismatched group (Table 2b) dence of limited and extensive chronic GVHD was comparable in the two groups, with a relatively low overall incidence (17%) of extensive chronic GVHD. Infectious diseases were only slightly but not significantly more frequent in the mismatched as compared with the matched group (Table 3) . Bacterial sepsis, CMV pneumonia, and toxoplasmosis were observed in both groups, whereas the 2 cases of aspergillosis occurred in the matched group.
Major causes of death were GVHD, infection, and leukemia relapse (Table 3) . Graft failure was observed in 2 patients, both of whom had chronic myelogenous leukemia (CML) treated with BMT more than 1 year (14 and 18 months) after diagnosis, with 1 in the first chronic phase and the other in blast crisis. Three of the four patients with acute leukemia receiving transplants in relapse died from a further relapse diagnosed between 90 and 861 days after BMT. In contrast, the 4 patients receiving transplants in advanced CML died from acute GVHD grade IV (2 patients), interstitial pneumonitis, and graft failure.
The TRM was significantly more frequent in mismatched than in matched grafts (Fig 1; P = .0072) . Similarly, the survival probability, according to Kaplan-Meier analysis, was significantly better for the matched than for the mismatched transplants (Fig 2; P = .0005 ).
In light of the known poor prognosis associated with transplantation in advanced disease stage, the comparison of matched and mismatched transplants was repeated after the exclusion of the 8 patients with advanced disease. The results were comparable to those obtained without exclusion of high-risk patients, with acute GVHD 111-IV being 23% and 54% ( P = .041), TRM 14% and 70% ( P = .0003), and 3-year survival probability 67% and 21% ( P = .0002) in matched (n = 21) and mismatched (n = 15) grafts, respectively.
The complete typing of all six classical HLA loci allowed the evaluation of HLA class I mismatches in class 11-matched BMT and vice versa. Therefore, we performed an additional analysis after splitting the mismatched transplants in two groups, ie, HLA class I-and HLA class 11-mismatched grafts, and compared them with the matched group defined above. 
No significant correlation was observed between matching
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The numbers of patients that could be evaluated for acute GVHD were 23 and 19 and for chronic GVHD were 20 and 9 for the matched and mismatched groups, respectively. Percentages indicate probabilities determined by the Kaplan-Meier method." HLA matching, GVHD, TRM, and survival did not differ significantly between the five participating transplantation centers (data not shown).
Abbreviation: n, number of patients.
' The numbers of patients with the causes considered to be (co)responsible for death are shown (1 or 2 causes per patient).
t Infections include CMV pneumonia (5), aspergillosis (21, bacterial sepsis (3). toxoplasmosis (1). and not specified (4).
and severe acute GVHD grades 111-IV (Table 4) . TRM was significantly higher in the HLA class 11 mismatched transplants. Finally, patient survival correlated significantly with both class I and class I1 mismatches.
DISCUSSION
In related BMT, the degree of HLA compatibility correlates with the incidence of posttransplant complication^.^.^ Unfortunately, the situation in unrelated BMT is less clear.'-'' Routine HLA typing techniques are sufficiently precise for the matching of siblings but are not suitable to detect minor polymorphic differences of human transplantation antigens. Therefore, unrelated patient-donor pairs are often mismatched for antigens not discriminated by conventional typing. The introduction of oligotyping for HLA class III4 has been a considerable step in progress and has recently allowed to show a significant correlation between HLA-DRB1 allele matching and GVHD.28.29 However, the clinical significance of high resolution HLA class I plus class I1 matching has not yet been shown. This lack of comprehensive HLA-matching studies is due to the low resolution of the routine HLA class I typing methods. Although DNA sequencing of donor and For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From The results of the 24 HLA-matched patients are the same as shown in Table 3 patient HLA genes allows the precise evaluation of individual HLA matching,12 further technologic progress is required before this approach can be applied routinely. Our strategy consisting of a combination of serology, cellular techniques, and oligotyping allowed identification of most HLA allele incompatibilities, whereas DNA sequencing was only necessary in the few remaining cases of previously not characterized allele^.'^^^^ The finding that patient survival was significantly better in the matched group indicates that HLA allele incompatibilities only detected by high resolution typing and missed by conventional techniques are clinically relevant. There were no major differences between the matched and the mismatched group with respect to demographics, diagnosis, risk factors, and treatment modalities, apart from an imbalance concerning the 8 patients receiving transplants in relapse, accelerated phase, or blast crisis. However, after the exclusion of these patients, the differences in TRM and patient survival remained statistically significant.
Moderate to severe GVHD grades 11-IV was frequently observed and did not correlate with the degree of HLA matching. However, in the HLA-mismatched group, the grades of acute liver and gut GVHD were significantly higher and severe acute GVHD 111-IV occurred more frequently. Therefore, the matched and mismatched groups differed in the severity but not in the incidence of GVHD. Interestingly, the overall incidence of severe acute GVHD grades 111-IV was rather low when compared with findings in other studies. '.l0 No major differences in the incidence of infectious diseases were observed between the two groups. However, the incidence of fatal infections was higher in the mismatched versus the matched group (10 v 5 ; Table 3 ). Therefore, the two groups differed in the severity rather than the incidence of infections. In contrast to the relatively low overall incidence of severe GVHD, the overall incidence of lethal infections was relatively high in our patients. This finding is in disagreement with some earlier observations showing a correlation between the rates of severe acute GVHD and infection." In our study, only 4 of the 15 patients with deathassociated infections suffered from severe acute GVHD III-IV. A possible explanation is that in vivo T-cell depletion and strong immunosuppressive therapy efficiently prevented severe acute GVHD but favored the development of severe infections. It is desirable to improve our means to predict GVHD to adapt GVHD prophylaxis individually for each patient. One step towards this goal is the precise characterization of HLA matching. Other GVHD influencing factors, such as minor transplantation antigens," bacterial infections,'2 irradiation, or pretransplant immune reactivity, must also be considered. New transplantation protocols, perhaps including the transfusion of large numbers of donor hematopoietic stem cells," may further reduce the incidence a n d or the severity of GVHD.
The frequency of HLA-C incompatibilities was relatively low, confirming the reported high linkage disequilibrium between the HLA-C and the HLA-B locus. The clinical results in the 5 patients with isolated HLA-C mismatches were as follows: severe acute aGVHD, 1 of 5; TRM, 2 of 5; and survival, 2 of 5. Thus, our study did not allow us to draw firm conclusions on a possible prognostic value of isolated HLA-C incompatibilities.
The CTLp test results were positive in all patient-donor pairs with HLA-A or -B mismatches.'6 In contrast, 2 of 5 patient-donor pairs with HLA-C mismatches had a negative CTLp test result, suggesting that HLA-C is not always stimulatory in primary in vitro CTL assays. Interestingly, the 2 HLA-C mismatched but CTLp-negative patients survived and had no or only moderate (grade 11) acute GVHD. This finding raises the hypothesis that HLA-C incompatib that are not in vitro stimulatory may be of low clinical relevance. However, more patients must be evaluated for an eventual confirmation.
In agreement with previous reports showing that HLA-DP antigens are very frequently mismatched,'2,'3.'s only 18% of the patient-donor pairs in our study were matched for HLA-DP. This is due to the considerable DPBl polymorphism and the low linkage disequilibrium between DPBl and DwDQ loci. For the majority of patients, it remains impossible to find an unrelated HLA-matched donor with HLA-DP compatibility, making it difficult to evaluate the clinical significance of HLA-DP mat~hing.'~.'~.'' By making the criteria for compatibility more severe, the chance of finding a matched donor decreases. To compensate for this, we analyzed up to 25 donors for those patients who had difficulties in finding a highly matched donor. We found that approximately 10 to 15 unrelated donors per patient can be analyzed within a reasonable time.34 Nevertheless, the patient's disease stage and treatment policy have to be taken into account for correct decisions on search and matching strategy. In urgent situations, such as aplastic anemia, it is not possible to prospectively perform extended time-consuming (cellular) investigations. However, in cases that are not urgent, there is usually sufficient time (ie, about 3 months) for the allocation of an optimal donor, if the donor search is started early after diagnosis. During 1994, our search and matching strategy has allowed us to find a highly HLA compatible (HLA-A, -B, -DRBl/B3/B5, -DQBl subtype-matched, and CTLp-negative) donor for 35% of our patients searching for an unrelated donor.
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We conclude that HLA allele mismatches are associated with increased posttransplant mortality. Although the patient groups were small and heterogeneous, the differences in clinical outcome were statistically significant. Nevertheless, our findings should be confirmed in larger patient populations. HLA typing on DNA sequence level will allow us to evaluate the clinical importance of mismatches of individual HLA alleles. In the future, this will eventually lead to the characterization of clinically acceptable mismatches."." Until then, avoiding incompatible donors by the selection of the most compatible available donor using high-resolution HLA typing may further improve the prognosis of patients undergoing unrelated BMT.
